Opinion|Videos|August 18, 2023
Unmet Needs in the Plaque Psoriasis Treatment Landscape
Author(s)Alexandra K. Golant, MD , Mona Shahriari, MD, FAAD
Expert dermatologists discuss plaque psoriasis patient populations that may not be ideal candidates for PDE-4 inhibitor treatment, as well as gaps that remain in the plaque psoriasis treatment landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Post hoc RESOLVE analysis shows that patients weighing at least 100 kg experience slower clinical response rates to brodalumab than those under 100 kg, establishing body weight over BMI as a key predictor of treatment timing.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss
2
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
3
Dersimelagon NDA Accepted by FDA with Priority Review for EPP, XLP
4
Maui Derm NP+PA Fall 2026 Day 2: GLP-1s, Inflammatory Disease, and Diagnostic Challenges
5